Cipla Targeted at Rs 1400 by Prabhudas Lilladher
Cipla's Q4FY26 Earnings Disappoint, FY27E Outlook Remains Challenging
Cipla's fourth quarter fiscal year 2026 (Q4FY26) earnings before interest, taxes, depreciation, and amortization (EBITDA) of INR 9.5 billion, with an operating profit margin (OPM) of 15%, fell short of Prabhudas Lilladher's estimates by 7%. This underperformance was primarily attributed to lower revenues in the US market.
Key Challenges Ahead
In the face of these challenges, management has provided guidance for fiscal year 2027 (FY27E), projecting an EBITDA margin of 18.5-20% at the exclusion of Lanreotide recovery. To address temporary supply disruptions, Cipla is pursuing an alternate US manufacturing site. Prabhudas Lilladher has revised its earnings per share (EPS) estimates for FY27E and FY28E, expecting a cut of 5-10% due to lower margins. The research firm forecasts Cipla's US annual sales run-rate at USD 800-950 million in FY27 and FY28, respectively.
Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
Critical Factors for Success
Two key factors will determine Cipla's success in the coming quarters. Firstly, timely approvals for critical respiratory products will be essential. Secondly, normalization of Lanreotide sales by the second half of FY27 will be crucial. In addition, Cipla's strong net cash position of $1.2 billion provides flexibility to pursue strategic mergers and acquisitions (M&A) opportunities.
Stock Valuation and Outlook
At the current market price (CMP), Cipla's stock is trading at 22 times its estimated earnings per share (EPS) for FY28. Given the high base of FY25 and FY26, led by Revlimid and Lanreotide, Prabhudas Lilladher expects flat EPS growth in FY27.
Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
| Revenue Growth (YoY) | FY25 | FY26 | FY27E | FY28E |
|---|---|---|---|---|
| US Sales | 20% | 15% | 10% | 8% |
| Global Sales | 12% | 8% | 5% | 4% |
Recommendation
Prabhudas Lilladher maintains its Accumulate rating on Cipla with a revised target price of INR 1,400 per share, valuing the stock at 23 times its estimated EPS for FY28. The timely launch of critical high-value products in the US in FY27 will be crucial for the company's success.
| Target Price | Current Price | Target Price Multiple |
|---|---|---|
| INR 1,400 | INR ? | 23x FY28E EPS |
Investor Takeaway
Investors should consider the potential impact of lower US revenues and margins on Cipla's earnings.
More in Market
Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
Indian Stocks to Watch: BHEL, Agarwal Industrial, JBM Auto, Rajesh Exports, Indian Energy Exchange, Lenskart Solutions in Market Focus on June 4.
